Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 11, Issue 2, pp. 233-236
PubMed
Published By
Print ISSN
Online ISSN
History
- Published first December 19, 2020.
Article Versions
- Previous version (December 19, 2020 - 06:40).
- Previous version (December 22, 2020 - 05:32).
- Previous version (January 4, 2021 - 05:52).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Antoni Ribas1,*,
- Rajarshi Sengupta2,
- Trevan Locke2,
- Sayyed Kaleem Zaidi2,
- Katie M. Campbell1,
- John M. Carethers3,
- Elizabeth M. Jaffee4,
- E. John Wherry5,
- Jean-Charles Soria6 and
- Gypsyamber D'Souza7 for the AACR COVID-19 and Cancer Task Force
- 1Department of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.
- 2American Association for Cancer Research, Philadelphia, Pennsylvania.
- 3Departments of Internal Medicine and Human Genetics and Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
- 4Department of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.
- 5Department of Systems Pharmacology and Translational Therapeutics, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- 6Paris Saclay University, Saint-Aubin, France and Drug Development Department, Gustave Roussy, Villejuif, France.
- 7Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
- ↵*Corresponding Author:
Antoni Ribas, Jonsson Comprehensive Cancer Center at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095. E-mail: aribas{at}mednet.ucla.edu
February 2021
Volume 11, Issue 2
Volume 11, Issue 2
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Jump to section
Advertisement